Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Substantial reduction in losses
Anti-malaria API facility will be operational in 15-18 months
It’s an AB-rated generic therapeutic version of Durezol
Demand normalisation post the second wave contributed to the steady growth
A treatment to prevent extreme symptoms and cut hospitalisation
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Subscribe To Our Newsletter & Stay Updated
